1. Home
  2. KPTI vs KNDI Comparison

KPTI vs KNDI Comparison

Compare KPTI & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • KNDI
  • Stock Information
  • Founded
  • KPTI 2008
  • KNDI 2002
  • Country
  • KPTI United States
  • KNDI China
  • Employees
  • KPTI N/A
  • KNDI N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • KNDI Auto Manufacturing
  • Sector
  • KPTI Health Care
  • KNDI Consumer Discretionary
  • Exchange
  • KPTI Nasdaq
  • KNDI Nasdaq
  • Market Cap
  • KPTI 81.1M
  • KNDI 91.2M
  • IPO Year
  • KPTI 2013
  • KNDI N/A
  • Fundamental
  • Price
  • KPTI $0.59
  • KNDI $1.09
  • Analyst Decision
  • KPTI Strong Buy
  • KNDI
  • Analyst Count
  • KPTI 4
  • KNDI 0
  • Target Price
  • KPTI $5.00
  • KNDI N/A
  • AVG Volume (30 Days)
  • KPTI 702.7K
  • KNDI 117.3K
  • Earning Date
  • KPTI 02-27-2025
  • KNDI 03-13-2025
  • Dividend Yield
  • KPTI N/A
  • KNDI N/A
  • EPS Growth
  • KPTI N/A
  • KNDI N/A
  • EPS
  • KPTI N/A
  • KNDI N/A
  • Revenue
  • KPTI $148,442,000.00
  • KNDI $118,127,232.00
  • Revenue This Year
  • KPTI $5.47
  • KNDI N/A
  • Revenue Next Year
  • KPTI $6.33
  • KNDI N/A
  • P/E Ratio
  • KPTI N/A
  • KNDI N/A
  • Revenue Growth
  • KPTI 1.77
  • KNDI N/A
  • 52 Week Low
  • KPTI $0.58
  • KNDI $0.89
  • 52 Week High
  • KPTI $1.70
  • KNDI $2.98
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 41.95
  • KNDI 50.35
  • Support Level
  • KPTI $0.60
  • KNDI $1.03
  • Resistance Level
  • KPTI $0.69
  • KNDI $1.12
  • Average True Range (ATR)
  • KPTI 0.05
  • KNDI 0.06
  • MACD
  • KPTI -0.00
  • KNDI -0.01
  • Stochastic Oscillator
  • KPTI 18.17
  • KNDI 26.92

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.

Share on Social Networks: